Zev A. Wainberg, MD, on Future Research Efforts for Patients With Advanced Gastric Cancer


Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal (GI) Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, highlighted future research efforts in the advanced gastric cancer space. Some of these pieces of research include large, randomized studies that will aim to further explore the role of pembrolizumab (Keytruda) within this patient population.


Obviously, the landscape has changed. We have frontline data with nivolumab [Opdivo], which has established it as the standard in [patients with a] CPS greater than 5 with chemotherapy. We have the [phase 3] KEYNOTE-811 study [NCT03615326], which established pembrolizumab plus chemotherapy plus trastuzumab [Herceptin] upfront in HER2-positive disease. There are 2 large, randomized phase 3 trials which will clarify the role of pembrolizumab a little bit further. There's something called the [phase 3 KEYNOTE-859] study [NCT03675737], which is a large, global study of pembrolizumab upfront with chemotherapy to look at whether there are any subsets in which you get benefit with chemotherapy plus pembrolizumab over chemotherapy alone. That study is still waiting to read out in the next year or so.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.